欢迎进入昊鑫官网

电话订购 · 意见建议400-861-5108

Laquinimod

Laquinimod

品 牌 MCE
C A S 号 248281-84-7
货 号 HY-13010
规 格 2mg
价 格(元) 800.00
咨询优惠价
货号 规格 价格
HY-13010 2mg 800.00
HY-13010 5mg 1200.00
HY-13010 10mg 2000.00
HY-13010 50mg 4500.00
HY-13010 100mg 7500.00
HY-13010 500mg 15000.00

产品说明


Laquinimod (ABR-215062)是免疫调节剂。



Laquinimod的生物活性


Laquinimod (ABR-215062) is a potent immunomodulator.
IC50 value:
Target: immunomodulator
Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS).
Laquinimod has demonstrated significant activity in suppressing experimental autoimmune encephalomyelitis, an animal model of RRMS. In phase I and II clinical trials, the drug was well tolerated, with some hints of efficacy in small numbers of patients with RRMS. While the mechanism of action of the drug is unknown, it likely involves Th1 to Th2/Th3 immune deviation, promotion of the synthesis and release of neurotrophic factors, and other possible neuroprotective effects. A Phase II study of Laquinimod in active lupus arthritis patients is currently ongoing, if successful, will lead to the approval of the first oral immunomodulatory drug for suppressing multiple sclerosis disease activity.

化学信息


分子量 356.8 储存条件 参考CoA中推荐的条件进行储存。
分子式 C₁₉H₁₇ClN₂O₃
CAS号 248281-84-7
溶剂/溶解度 10 mM in DMSO

相关文献


[1]. Brueck, Wolfgang; Zamvil, Scott S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Clinical Pharmacology (2012), 5(3), 245-256.
[2]. Schulze-Topphoff, Ulf; Shetty, Aparna; Varrin-Doyer, Michel et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012), 7(3), e33797.
[3]. Toubi E, Nussbaum S, Staun-Ram E et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol. 2012 Oct 15;251(1-2):45-54.
[4]. Th?ne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011 Mar;7(3):365-70.
[5]. Tselis A. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis. Curr Opin Investig Drugs. 2010 May;11(5):577-85.